Maurel S, De Vry J, De Beun R, Schreiber R
CNS Research, Bayer AG, Cologne, Germany.
Pharmacol Biochem Behav. 1999 Jan;62(1):89-96. doi: 10.1016/s0091-3057(98)00115-4.
The present study aimed to investigate the role of serotonin 5-HT2A and 5-HT2C receptors in the control of alcohol preference and consummatory behavior in alcohol-preferring cAA rats. Effects of the 5-HT(2A/2C) receptor agonist, DOI, the 5-HT(2C/1B) receptor agonist, mCPP, the 5-HT(2A/2C) receptor antagonist, ritanserin, and the 5-HT2A receptor antagonist, MDL 100,907, on ethanol (EtOH, 10% v/v) preference and intake, as well as total fluid and food intake were evaluated in a 12-h limited-access two-bottle paradigm. DOI (0.3-3 mg/kg, i.p.) reduced EtOH intake and preference, but not total fluid or food intake; whereas mCPP (1-10 mg/kg, s.c.) reduced EtOH, total fluid, and food intake. Therefore, it is concluded that DOI induces a specific and selective antialcohol effect, whereas mCPP rather induces a general suppressive effect on consummatory behavior. Ritanserin (1-10 mg/kg, i.p.) did not affect EtOH intake and preference, nor total fluid and food consumption. MDL 100,907 (0.1-1 mg/kg, i.p.) induced only a small reduction of food intake at the highest dose tested. Pretreatment with ritanserin (3 mg/kg, i.p.) and MDL 100,907 (0.3 mg/kg, i.p.) blocked the effects of DOI (3 mg/kg, i.p.), but not those of mCPP (10 mg/kg, i.p.). It is suggested that activation of 5-HT2C and/or 5-HT1B receptors results in a general decrease of consummatory behavior, whereas activation of 5-HT2A receptors selectively decreases EtOH intake and preference, as assessed in the cAA rat model of alcoholism.
本研究旨在探讨血清素5-HT2A和5-HT2C受体在酒精偏好型cAA大鼠的酒精偏好及消费行为控制中的作用。在12小时限时两瓶范式中,评估了5-HT(2A/2C)受体激动剂DOI、5-HT(2C/1B)受体激动剂mCPP、5-HT(2A/2C)受体拮抗剂利坦色林和5-HT2A受体拮抗剂MDL 100,907对乙醇(EtOH,10% v/v)偏好和摄入量以及总液体和食物摄入量的影响。DOI(0.3 - 3毫克/千克,腹腔注射)减少了EtOH摄入量和偏好,但不影响总液体或食物摄入量;而mCPP(1 - 10毫克/千克,皮下注射)减少了EtOH、总液体和食物摄入量。因此,得出结论:DOI诱导了一种特异性和选择性抗酒精作用,而mCPP更倾向于对消费行为产生一般性抑制作用。利坦色林(1 - 10毫克/千克,腹腔注射)不影响EtOH摄入量和偏好,也不影响总液体和食物消耗。MDL 100,907(0.1 - 1毫克/千克,腹腔注射)在测试的最高剂量下仅引起食物摄入量的小幅减少。用利坦色林(3毫克/千克,腹腔注射)和MDL 100,907(0.3毫克/千克,腹腔注射)预处理可阻断DOI(3毫克/千克,腹腔注射)的作用,但不能阻断mCPP(10毫克/千克,皮下注射)的作用。提示在酒精中毒的cAA大鼠模型中评估发现,5-HT2C和/或5-HT1B受体的激活导致消费行为普遍下降,而5-HT2A受体的激活选择性地降低EtOH摄入量和偏好。